TUBACEX adapts its Organization to fight COVID-19: Q3 Results

TUBACEX’s sales figure for the first nine months of the year amounts to €389.6 million, which is 18.2% lower than that of the same period last year; while EBITDA stands at €26.4 million, down 42.9%, with a 6.8% margin. These results, determined by the global...

The 50% fall in the market and COVID-19 mark TUBACEX’s results

The sales figure for the first half of the year amounts to €282 M, down 12.8% on the same period last year, and the EBITDA stands at €19.8 M, 40.5% less. These figures are a far cry from TUBACEX’s prospects at the start of the year but, even in such an unfavorable...

TUBACEX presents its results in a market context dominated by COVID-19

2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.